TY - JOUR
T1 - Management of supine hypertension in patients with neurogenic orthostatic hypotension
T2 - scientific statement of the American Autonomic Society, European Federation of Autonomic Societies, and the European Society of Hypertension
AU - Jordan, Jens
AU - Fanciulli, Alessandra
AU - Tank, Jens
AU - Calandra-Buonaura, Giovanna
AU - Cheshire, William P
AU - Cortelli, Pietro
AU - Eschlboeck, Sabine
AU - Grassi, Guido
AU - Hilz, Max J
AU - Kaufmann, Horacio
AU - Lahrmann, Heinz
AU - Mancia, Giuseppe
AU - Mayer, Gert
AU - Norcliffe-Kaufmann, Lucy
AU - Pavy-Le Traon, Anne
AU - Raj, Satish R
AU - Robertson, David
AU - Rocha, Isabel
AU - Reuter, Hannes
AU - Struhal, Walter
AU - Thijs, Roland D
AU - Tsioufis, Konstantinos P
AU - Gert van Dijk, J
AU - Wenning, Gregor K
AU - Biaggioni, Italo
N1 - Funding Information:
J.J. served as consultant for Theravance in the development of therapies for orthostatic hypotension. G.C.-B. has received speaker honoraria from Chiesi Farmaceutici, Abb-Vie srl, and UCB Pharma S.p.A., P.C. has received honoraria for speaking engagements or consulting activities from Allergan Italia, AbbVie srl, Chiesi Farmaceutici, Eli Lilly, Novartis, Teva, UCB Pharma S.p.A., and ZambonGM has received speaker’s fees from Boehringer Ingelheim, Ferrer, Medtronic Vascular Inc, Menarini Int, Merck Serono, Novar-tis, Recordati, and Servier, A.P.-L.T. received research funding from the French Health Ministry, R.D.T. receives research support from the Dutch National Epilepsy Fund, The Netherlands Organization for Health Research and Development (ZonMW), NUTS Ohra Fund, Medtronic, and AC Thomson Foundation, and has received fees for lectures from Medtronic, UCB, and GSK. I.B. was a consultant for Lundbeck in the development of droxidopa, and is a consultant for Theravance in the development of therapies for orthostatic hypotension. He has submitted a patent application for an automated abdominal binder for the treatment of orthostatic hypotension. I.B. was supported in part by National Institutes of Health grants Grant P01 HL056693, R01 HL122847, U54 NS065736, and UL1 RR024975 (Clinical and Translational Science Award). A.F., J.T., G.C.-B., W.P.C., P.C., S.E., G.G., M.J.H., H.K., H.L., G.M., L.N.-K., S.R.R., D.R., I.R., H.R., W.S., K.P.T., J.G.v.D., G.K.W. declare no conflicts of interest.
Publisher Copyright:
© 2019 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2019/8/1
Y1 - 2019/8/1
N2 - : Supine hypertension commonly occurs in patients with neurogenic orthostatic hypotension due to autonomic failure. Supine hypertension promotes nocturnal sodium excretion and orthostatic hypotension, thus, interfering with quality of life. Perusal of the literature on essential hypertension and smaller scale investigations in autonomic failure patients also suggest that supine hypertension may predispose to cardiovascular and renal disease. These reasons provide a rationale for treating supine hypertension. Yet, treatment of supine hypertension, be it through nonpharmacological or pharmacological approaches, may exacerbate orthostatic hypotension when patients get up during the night. Fall-related complications may occur. More research is needed to define the magnitude of the deleterious effects of supine hypertension on cardiovascular, cerebrovascular, and renal morbidity and mortality. Integration of more precise cardiovascular risk assessment, efficacy, and safety data, and the prognosis of the underlying condition causing autonomic failure is required for individualized management recommendations.
AB - : Supine hypertension commonly occurs in patients with neurogenic orthostatic hypotension due to autonomic failure. Supine hypertension promotes nocturnal sodium excretion and orthostatic hypotension, thus, interfering with quality of life. Perusal of the literature on essential hypertension and smaller scale investigations in autonomic failure patients also suggest that supine hypertension may predispose to cardiovascular and renal disease. These reasons provide a rationale for treating supine hypertension. Yet, treatment of supine hypertension, be it through nonpharmacological or pharmacological approaches, may exacerbate orthostatic hypotension when patients get up during the night. Fall-related complications may occur. More research is needed to define the magnitude of the deleterious effects of supine hypertension on cardiovascular, cerebrovascular, and renal morbidity and mortality. Integration of more precise cardiovascular risk assessment, efficacy, and safety data, and the prognosis of the underlying condition causing autonomic failure is required for individualized management recommendations.
KW - Humans
KW - Hypertension/complications
KW - Hypotension, Orthostatic/complications
KW - Quality of Life
KW - Societies, Medical/organization & administration
KW - Supine Position/physiology
UR - http://www.scopus.com/inward/record.url?scp=85069237048&partnerID=8YFLogxK
U2 - 10.1097/HJH.0000000000002078
DO - 10.1097/HJH.0000000000002078
M3 - Journal article
C2 - 30882602
SN - 0263-6352
VL - 37
SP - 1541
EP - 1546
JO - Journal of Hypertension
JF - Journal of Hypertension
IS - 8
ER -